FSD Pharma Inc. Changes Name to Quantum BioPharma Ltd.

Ticker: QNTM · Form: 6-K · Filed: Aug 15, 2024 · CIK: 1771885

Fsd Pharma Inc. 6-K Filing Summary
FieldDetail
CompanyFsd Pharma Inc. (QNTM)
Form Type6-K
Filed DateAug 15, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: corporate-action, name-change, rebranding

TL;DR

FSD Pharma is now Quantum BioPharma Ltd. - new name, same SEC filings.

AI Summary

Quantum BioPharma Ltd., formerly FSD Pharma Inc., announced on August 15, 2024, the completion of its corporate name change. This change is incorporated by reference into the Company's Registration Statement on Form F-3 (SEC File No. 333-276264). The company is a foreign private issuer based in Toronto, Ontario, Canada.

Why It Matters

The name change signifies a potential rebranding or strategic shift for the company, which could impact investor perception and market positioning.

Risk Assessment

Risk Level: low — This filing is a routine corporate update regarding a name change and does not introduce new financial or operational risks.

Key Numbers

  • 001-39152 — SEC File Number (Commission file number for FSD Pharma Inc. / Quantum BioPharma Ltd.)

Key Players & Entities

  • Quantum BioPharma Ltd. (company) — Current company name
  • FSD Pharma Inc. (company) — Former company name
  • August 15, 2024 (date) — Date of press release and name change announcement
  • 333-276264 (other) — SEC File Number for Registration Statement on Form F-3

FAQ

What was the previous name of Quantum BioPharma Ltd.?

Quantum BioPharma Ltd. was formerly known as FSD Pharma Inc.

When was the name change announced?

The name change was announced on August 15, 2024.

What is the SEC file number for the company's Registration Statement on Form F-3?

The SEC file number is 333-276264.

Where is the principal executive office of Quantum BioPharma Ltd. located?

The principal executive office is located at 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada.

Does the company file annual reports under Form 20-F or 40-F?

The company indicates it files annual reports under Form 20-F.

Filing Stats: 319 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2024-08-15 07:07:30

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: August 15, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 3 EXHIBIT INDEX Exhibit Description Exhibit 99.1 Press Release dated August 15, 2024 – FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation – Trading under New Ticket Symbol "QNTM" 4

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.